Assembly Biosciences, Inc. (ASMB)

Market Cap	395.07M
Revenue (ttm)	33.25M
Net Income (ttm)	-38.96M
Shares Out	15.56M
EPS (ttm)	-5.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	147,675
Open	25.90
Previous Close	25.89
Day's Range	25.35 - 26.00
52-Week Range	7.75 - 27.17
Beta	0.65
Analysts	Strong Buy
Price Target	38.67 (+52.3%)
Earnings Date	Aug 6, 2025

About ASMB

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinica...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 17, 2010
• Employees: 73
• Stock Exchange: NASDAQ
• Ticker Symbol: ASMB
• Website: https://www.assemblybio.com

Financial Performance

In 2024, Assembly Biosciences's revenue was $28.52 million, an increase of 298.16% compared to the previous year's $7.16 million. Losses were -$40.18 million, -34.38% less than in 2023.

Analyst Summary

According to 4 analysts, the average rating for ASMB stock is "Strong Buy." The 12-month stock price target is $38.67, which is an increase of 52.30% from the latest price.

Price Target

$38.67

(52.30% upside)

Analyst Consensus: Strong Buy